Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
This document is in .pdf format and can be downloaded at the bottom of this page.
In this issue:
Drug safety advice
- Piroxicam: new restrictions, including specialist initiation
- Ketoprofen and ketorolac: gastrointestinal risk
- Inhaled corticosteroids: pneumonia
- Pneumovax II: tolerability of re-vaccination
- Bisphosphonates: osteonecrosis of the jaw
- Lorazepam: reduction of recommended maximum daily dose
Yellow Card scheme update
- Please continue to report
Hot topics
- Botulinum toxin products: rare but serious risk
- Rosiglitazone and pioglitazone: cardiovascular safety and fracture risk
Stop press
- Recent letters to healthcare professionals
- Lumiracoxib and hepatotoxicity: prescribing update
- Latest safety information
Other information from the MHRA
- Field safety notices for medical devices
- Consultation—MHRA strategy
Drug Safety Update: Volume 1, Issue 3, October 2007 
